Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: A tag enhances vehicle radar visibility of objects by increasing the effective radar cross-section of the object, allowing detection at longer ranges and providing the vehicle/driver with more time to avoid a collision. The tag may include a receive antenna and a bandpass filter configured to receive a signal from the receive antenna and to allow a portion of the frequency range of the signal from the receive antenna through. The tag may also include an amplifier configured to receive and amplify the signal with the portion of the frequency range from the bandpass filter. The tag may further include a transmit antenna configured to transmit the amplified signal. The receive antenna, the transmit antenna, and the amplifier may be configured such that antenna-to-antenna isolation between the receive antenna and the transmit antenna is greater than a gain of the amplifier.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: Provided herein are methods of treating a subject that include administering a therapeutically effective amount of an NLPR3 antagonist or a pharmaceutically acceptable salt, solvate, or co-crystal thereof to a subject identified as having a cell that has an elevated level of NLRP3 inflammasome activity and/or expression as compared to a reference level. Provided herein are methods of treating a subject, methods of selecting a treatment for a subject, methods of selecting a subject for treatment, and methods of selecting a subject for participation in a clinical study that include the administration of a therapeutically effective amount of an NLRP3 antagonist. Also provided are methods of treating a subject having resistance to an anti-TNF? agent and methods of determining the efficacy of treatment with an anti-TNF? agent. Also provided are methods of treating a subject with a combination of an NLRP3 antagonist and an anti-TNF? agent.

Abstract: A tag enhances vehicle radar visibility of objects by increasing the effective radar cross-section of the object, allowing detection at longer ranges and providing the vehicle/driver with more time to avoid a collision. The tag may include a receive antenna and a bandpass filter configured to receive a signal from the receive antenna and to allow a portion of the frequency range of the signal from the receive antenna through. The tag may also include an amplifier configured to receive and amplify the signal with the portion of the frequency range from the bandpass filter. The tag may further include a transmit antenna configured to transmit the amplified signal. The receive antenna, the transmit antenna, and the amplifier may be configured such that antenna-to-antenna isolation between the receive antenna and the transmit antenna is greater than a gain of the amplifier.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to treat connected to the modulation of NRLP3.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured. The variables shown in Formula AA are as defined in the claims. The compounds of formula AA are NLRP3 activity modulators and, as such, can be used in the treatment of metabolic disorders (e.g. Type 2 diabetes, atherosclerosis, obesity or gout), a disease of the central nervous system (e.g. Alzheimer's disease, multiple sclerosis, Amyotrophic Lateral Sclerosis or Parkinson's disease), lung disease (e.g. asthma, COPD or pulmonary idiopathic fibrosis), liver disease (e.g. NASH syndrome, viral hepatitis or cirrhosis), pancreatic disease (e.g. acute pancreatitis or chronic pancreatitis), kidney disease (e.g. acute kidney injury or chronic kidney injury), intestinal disease (e.g. Crohn's disease or Ulcerative Colitis), skin disease (e.g. psoriasis), musculoskeletal disease (e.g. scleroderma), a vessel disorder (e.g. giant cell arteritis), a disorder of the bones (e.g.

Abstract: A cutter head for a brushcutter has a base member with top and bottom base member parts and rotates about an axis of rotation in operation. The top base member part is fixed to the brushcutter shaft end. The bottom base member part is screwed by a screw element to the shaft end. A bearing element is arranged in the base member radially spaced to the axis of rotation. A cutting tool is secured by the bearing element to the base member between top and bottom base member parts. The bearing element is secured either to bottom or top base member part and arranged relative to the other one such that the bearing element is constructively unhindered to move relative to the other base member part at least circumferentially and such that the bottom base member part for mounting or demounting is rotatable relative to the top base member part.

Abstract: A rotatingly drivable filament cutting head for a trimmer, having a basic body on which a cutting filament is held. The cutting filament extends from outside the basic body through an opening into an interior region of the filament cutting head open to the surrounding area. A stop is arranged on the filament cutting head, so that, in a first position of the cutting filament, the stop delimits a filament portion of the cutting filament, which is insertable into the interior region, to an insertion length. A deflection element is arranged in the interior region so that the cutting filament can be switched from its first position, without the cutting filament being longitudinally displaced, into a second position. The cutting filament abuts against the deflection element in its second position and the stop does not delimit the length of the filament portion which is insertable into the interior region.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

Abstract: The cutting knife has a base member with first and second faces. One face has a topographic disturbance element arranged between knife edge and longitudinal center axis and shaping the elevation profile of the face. On the opposite face relative to the center plane an opposite elevation profile with contour line is formed. The contour line points of the contour line of the first elevation profile are positioned opposite the contour line points of the opposite contour line on perpendiculars to the center plane. The contour line of the first elevation profile and the opposite contour line are noncongruent. The contour line of the first elevation profile extends transversely to the longitudinal center axis of the base member across the disturbance element and has an ascending line section and a descending line section. A turning point positioned between these line sections is a component of the disturbance element.